Cybrexa Therapeutics
Sophia Gayle began their work experience in 2013 at LAM Therapeutics, where they held roles as a Research Scientist from October 2013 to December 2014, and later as a Senior Research Scientist from January 2015 to December 2018. In 2019, they transitioned to Cybrexa Therapeutics and initially served as an Associate Director of Biology until January 2022, when they took on the role of Director of Biology.
Sophia Gayle earned their Bachelor of Science (BSc) degree in Biology from Duke University, graduating between 2003 and 2007. Subsequently, they pursued their academic career at Yale University, where they completed their PhD in Genetics from 2007 to 2013.
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.